Alcon (2U3) Stock Price & Analysis

4 Followers

2U3 Stock Chart & Stats

€67.26€0.70(0.09%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 66.56 - EUR 67.32
52-Week Range: EUR 52.42 - EUR 74.62
Previous Close: EUR 67.20
Volume: N/A
Average Volume (3M): 3,245
Market Cap: EUR 33.54B
Enterprise Value: EUR 29.78B
Total Cash (Recent Filing): EUR 1.46B
Total Debt (Recent Filing): EUR 5.31B
Price to Earnings (P/E): 57.0
Beta: 0.81
Next Earnings: Mar 02, 2027 (Est.)
EPS Estimate: 0.83
Next Dividend Ex-Date: N/A
Dividend Yield: 0.46%

Bulls Say, Bears Say

Bulls Say

Recurring, Diversified Eye-care Model

Alcon's two-segment model combines procedure-linked surgical consumables with contact lenses and ocular-health products. Its surgical equipment installed base can generate repeat consumables, service, and upgrade demand, while lens replacement cycles add recurring purchasing and revenue resilience.

Broad Innovation And Product Pipeline

A broad launch and innovation pipeline can extend growth beyond existing products. Management cites Vivity Pro, TruPlus, PanOptix Pro, Tryptyr, BRYTLY, UNITY, Valeda and Neurotech, with above-market sales growth expected in 2027, supporting portfolio renewal.

Strong Cash Generation And Conservative Leverage

Alcon's financial capacity is supported by low-to-moderate leverage and substantial cash generation. Free cash flow reached $1.81 billion in 2025 and $1.71 billion TTM, while more than $1.3 billion was generated in the first nine months, enabling investment and capital returns.

Bears Say

Recent Profitability And Return Deterioration

Recent earnings quality has weakened despite steady sales and a healthy gross-margin base. TTM net margin fell to about 5.9% from roughly 9%–10% in 2024–2025, operating profitability also declined, and ROE fell to about 2.9%, reducing current earnings efficiency.

Premium IOL Competitive Pressure

Competitive intensity is pressuring Alcon's premium implantable franchise. Implantable sales declined 2% and U.S. premium IOL share fell, with management expecting competitive activity through early next year; sustained share pressure could limit pricing and growth in a strategic category.

Structural Cataract-market Constraints

Demand conditions are constrained in important procedure markets. Cataract growth remains below historical levels because of U.S. capacity constraints and international reimbursement and hospital economics, limiting procedure-volume growth that supports surgical consumables and equipment utilization.

Alcon News

Alcon Earnings Call Shows Growth Amid Rising Headwinds

Alcon (($CH:ALC)) has held its Q3 earnings call. Read on for the main highlights of the call. Alcon’s earnings call carried a broadly positive tone, supported by 5% quarterly sales

54m agoALC 2U3

Midday Fly By: CoreWeave reports beat and raise, OpenAI revenue jumps 50% in Q3

The major averages were higher near noon, led by a big rebound in the Nasdaq as a better-than-expected quarterly report from CoreWeave helped ease concerns around the sustainability of AI

8h agoC DB

Morning Movers: CoreWeave rises after guidance boost

Stock futures are higher, led by a sharp rebound in technology shares as stronger-than-expected results from CoreWeave helped ease concerns around the sustainability of AI infrastructure spending. Nasdaq 100 futures

11h agoALC GIB

Closing Bell Movers: CoreWeave rallies after results

Hotter than expected CPI data on Tuesday thwarted two days worth of gains across the major average, sending Nasdaq Composite down by 0.7% and the S&P 500 by 0.4%. The

23h agoBV NN

Alcon Reports Third-Quarter Results, Cites Neurotech Acquisition

Alcon ( ($CH:ALC) ) just unveiled an update. On Nov. 10, 2026, Alcon reported third-quarter sales of $2.7 billion, up 5% year over year on reported and constant-currency bases, with

1d ago6K ALC

Alcon reports Q3 EPS 91c, consensus 89c

Reports Q3 revenue $2.71B, consensus $2.74B. “We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas

1d agoALC 2U3

Alcon narrows FY26 EPS growth view to 12%-14% from 12%-15%

Consensus $3.50. Narrows FY26 revenue growth view to 6% from up 5%-7%, consensus $11.08B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

1d agoALC 2U3

Alcon (ALC) Q3 Earnings Cheat Sheet

Alcon (ALC) is scheduled to report 3rd quarter earnings on 11/10/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Alcon to post earnings of CHF0.72 per share.

3d agoALC 2U3

Alcon price target lowered to $84 from $88 at KeyBanc

KeyBanc lowered the firm’s price target on Alcon (ALC) to $84 from $88 and keeps an Overweight rating on the shares. While the firm remains confident in visibility toward Alcon’s

2w agoALC 2U3

Alcon acquires Neurotech and expands retina portfolio with ENCELTO

Alcon (ALC) announced it has acquired Neurotech Pharmaceuticals, a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alcon’s retina portfolio with ENCELTO,

3w agoALC 2U3

Alcon announces FDA approval of Brytly Redness Reliever Eye Drops

Alcon (ALC) announced that the U.S. FDA has approved Brytly Redness Reliever Eye Drops. With one drop, Brytly works in just one minute to significantly reduce redness and delivers up

3w agoALC 2U3

Alcon price target lowered to $80 from $85 at Mizuho

Mizuho lowered the firm’s price target on Alcon (ALC) to $80 from $85 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and

4w agoALC 2U3

Alcon price target lowered to $74 from $82 at BTIG

BTIG lowered the firm’s price target on Alcon (ALC) to $74 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q3

1M agoALC 2U3

Alcon: Underperform Rating Reiterated as Analyst Flags Mounting Headwinds; $48 Price Target Maintained

In a report released yesterday, Julien Ouaddour from Bank of America Securities reiterated a Sell rating on Alcon, with a price target of CHF48.00. Julien Ouaddour has given his Sell

1M agoALC 2U3

2U3 FAQ

What was Alcon’s price range in the past 12 months?

Alcon lowest stock price was €52.42 and its highest was €74.62 in the past 12 months.

What is Alcon’s market cap?

Alcon’s market cap is €33.54B.

When is Alcon’s upcoming earnings report date?

Alcon’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 110 days.

How were Alcon’s earnings last quarter?

Alcon released its earnings results on Nov 10, 2026. The company reported €0.821 earnings per share for the quarter, beating the consensus estimate of €0.78 by €0.041.

Is Alcon overvalued?

According to Wall Street analysts Alcon’s price is currently Undervalued.

Does Alcon pay dividends?

Alcon does not currently pay dividends.

What is Alcon’s EPS estimate?

Alcon’s EPS estimate is 0.83.

How many shares outstanding does Alcon have?

Alcon has 499,700,000 shares outstanding.

What happened to Alcon’s price movement after its last earnings report?

Alcon reported an EPS of €0.821 in its last earnings report, beating expectations of €0.78. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Alcon?

Hedge funds hold Alcon shares: the largest hedge-fund position in Alcon is 1,515,441,158 shares, and hedge funds decreased their holdings by 352.4K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alcon Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Alcon

Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.

Alcon (2U3) Earnings & Revenues

Historic Earnings Reports

2U3 Company Deck

2U3 Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call was broadly positive. Alcon delivered 5% quarterly sales growth, 6% year-to-date growth, 15% core EPS growth, strong free cash flow and meaningful capital returns, while reporting momentum in equipment, contact lenses, ocular health and new product launches. The company also highlighted a broad innovation pipeline, the Neurotech acquisition and continued efficiency initiatives. The main negatives were competitive pressure in U.S. premium IOLs, softer international contact lens conditions, eye care markets at the low end of expectations, narrowed 2026 profitability guidance and several identified 2027 headwinds.

View all DE:2U3 earnings summaries

2U3 Stock 12 Month Forecast

Average Price Target

EUR 74.72▲(11.09% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

HighEUR 92.20

AverageEUR 74.72

LowEUR 52.06

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	14	6	2
Technical Analysis	3	6	1
Moving Averages	11	0	1

Technical Analysis >

Similar Stocks

Stocks similar to DE:2U3
Company	Price & Change	Follow
CH:ROPRoche Holding AG
CH:STMNStraumann Holding AG
CH:SFZNSiegfried Holding AG
CH:TECNTecan Group AG
CH:MEDXmedmix AG

Compare DE:2U3 Stocks >

Ownership Overview

11.54% Mutual Funds
4.92% Other Institutional Investors
66.92% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft